patients with cancer, fatigue is experienced by 80% of individuals who receive chemotherapy and/or radiotherapy. 4 , 5 In patients with metastatic disease, the prevalence of cancer-related fatigue (CRF) exceeds 75%. 6 – 9 Using a cutpoint of 4 or higher
Search Results
Ann M. Berger, Kathi Mooney, Amy Alvarez-Perez, William S. Breitbart, Kristen M. Carpenter, David Cella, Charles Cleeland, Efrat Dotan, Mario A. Eisenberger, Carmen P. Escalante, Paul B. Jacobsen, Catherine Jankowski, Thomas LeBlanc, Jennifer A. Ligibel, Elizabeth Trice Loggers, Belinda Mandrell, Barbara A. Murphy, Oxana Palesh, William F. Pirl, Steven C. Plaxe, Michelle B. Riba, Hope S. Rugo, Carolina Salvador, Lynne I. Wagner, Nina D. Wagner-Johnston, Finly J. Zachariah, Mary Anne Bergman, and Courtney Smith
William Breitbart and Yesne Alici
S everal pharmacologic agents have been considered and studied for the treatment of cancer-related fatigue, including psychostimulants, antidepressants, megestrol acetate, and amantadine. 1 A recent meta-analysis of pharmacologic treatment
Margaret L. McNeely and Kerry S. Courneya
O ver the past decade, a significant increase has occurred in the amount and quality of research examining the role of exercise in managing cancer-related fatigue (CRF). 1 – 5 In fact, a recent systematic review noted that CRF is the most
Joanne E. Mortimer, Andrea M. Barsevick, Charles L. Bennett, Ann M. Berger, Charles Cleeland, Shannon R. DeVader, Carmen Escalante, Jeffrey Gilreath, Arti Hurria, Tito R. Mendoza, and Hope S. Rugo
T he NCCN Cancer-Related Fatigue (CRF) Scientific Research Committee was convened in September 2009 to accomplish 3 objectives: 1) review the current methods to measure and interventions to treat CRF; 2) recommend a CRF measure or develop a new
Ann M. Berger, Amy Pickar Abernethy, Ashley Atkinson, Andrea M. Barsevick, William S. Breitbart, David Cella, Bernadine Cimprich, Charles Cleeland, Mario A. Eisenberger, Carmen P. Escalante, Paul B. Jacobsen, Phyllis Kaldor, Jennifer A. Ligibel, Barbara A. Murphy, Tracey O'Connor, William F. Pirl, Eve Rodler, Hope S. Rugo, Jay Thomas, and Lynne I. Wagner
is experienced by 70% to 100% of patients with cancer who undergo multi-modal treatments and dose–dense, dose-intense protocols. 11 In patients with metastatic disease, the prevalence of cancer-related fatigue exceeds 75%. Cancer survivors report
Barbara F. Piper and David Cella
How cancer-related fatigue (CRF) is defined can affect how specific subtypes are identified. The most commonly used definition is the one proposed by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Cancer-Related Fatigue (in this
Carmen P. Escalante, Ellen Manzullo, and Rosalie Valdres
The authors receive grant funding from Ortho Biotech Oncology. References 1 Mock V Atkinson A Barsevick A NCCN cancer-related fatigue clinical practice guidelines in oncology . Oncology 2000 ; 14 : 151 – 161 . 2
Antonio Di Meglio, Cecile Charles, Elise Martin, Julie Havas, Arnauld Gbenou, Jean-Daniel Flaysakier, Anne-Laure Martin, Sibille Everhard, Enora Laas, Nicolas Chopin, Laurence Vanlemmens, Christelle Jouannaud, Christelle Levy, Olivier Rigal, Marion Fournier, Patrick Soulie, Florian Scotte, Barbara Pistilli, Agnes Dumas, Gwenn Menvielle, Fabrice André, Stefan Michiels, Sarah Dauchy, and Ines Vaz-Luis
these, cancer-related fatigue (CRF) is extremely common and persistent. 5 – 8 Compared with fatigue experienced by individuals without cancer, CRF is described as more intense, distressing, and less responsive to rest. 9 – 11 Its manifestations can
William Breitbart and Yesne Alici-Evcimen
. Curt GA Breitbart W Cella D . Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition . Oncologist 2000 ; 5 : 353 – 360 . 2. Hwang SS Chang VT Rue M Kasimis B . Multidimensional independent
Nina Wagner-Johnston
Treatment for Cancer-Related Fatigue Overview The NCCN Cancer-Related Fatigue Panel defines the condition as “a distressing, persistent, subjective sense of tiredness or exhaustion related to cancer or cancer treatment that is not
